Details

<p>Preface viii</p> <p>Organizations Associated with the TNM System xiii</p> <p>National Committees xiii</p> <p>Acknowledgements xv</p> <p>Abbreviations xvi</p> <p><b>Chapter 1 Explanatory Notes – General</b></p> <p>The General Rules of the TNM System 1</p> <p>The TNM Clinical and Pathological Classifications 7</p> <p>Residual Tumour (R) Classification 15</p> <p>Additional Descriptors 20</p> <p>Optional Descriptors 24</p> <p>Unknown Primary 25</p> <p>Staging of Tumours for Which No TNM Classification is Provided 25</p> <p>Histopathological Grading 26</p> <p>References 28</p> <p><b>Chapter 2 Explanatory Notes – Specific Anatomical Sites</b></p> <p>Head and Neck Tumours 34</p> <p>Digestive System Tumours 54</p> <p>Lung, Pleural and Thymic Tumours 85</p> <p>Bone Tumours 104</p> <p>Soft Tissue Tumours 106</p> <p>Gastrointestinal Stromal Tumour (GIST) 108</p> <p>Skin Tumours 110</p> <p>Breast Tumours 118</p> <p>Gynaecological Tumours 122</p> <p>Urological Tumours 131</p> <p>Ophthalmic Tumours 142</p> <p>Hodgkin and Non‐Hodgkin Lymphomas 149</p> <p>References 150</p> <p><b>Chapter 3 Site‐Specific Requirements for pT and pN</b></p> <p>Introduction 157</p> <p>Head and Neck Tumours 160</p> <p>Digestive System Tumours 166</p> <p>Lung and Pleural Tumours 173</p> <p>Tumours of Bone and Soft Tissues 176</p> <p>Skin Tumours 179</p> <p>Breast Tumours 183</p> <p>Gynaecological Tumours 185</p> <p>Urological Tumours 188</p> <p>Adrenal Cortex Tumours 192</p> <p>Ophthalmic Tumours 193</p> <p>Hodgkin and Non‐Hodgkin Lymphomas 195</p> <p>References 196</p> <p><b>Chapter 4 New TNM Classifications Recommended for Testing and Other Classifications</b></p> <p>Introduction 198</p> <p>General 198</p> <p>Specific 198</p> <p>Non Upper Aerodigestive Tract Mucosal Melanoma 199</p> <p>Primary Liver Carcinoma of Infants and Children/Hepatoblastoma 200</p> <p>Primary Cutaneous Lymphomas 202</p> <p>Cutaneous T‐Cell Lymphomas 202</p> <p>Primary Cutaneous Lymphomas 203</p> <p>Histopathologic Staging of Lymph Nodes in Mycosis Fungoides and Sézary Syndrome 204</p> <p>Primary Cutaneous B‐Cell/T‐Cell Lymphoma (Non‐MF/SS Lymphoma) 206</p> <p>Multiple Myeloma 207</p> <p>Leukaemia 208</p> <p>References 208</p> <p><b>Chapter 5 Optional Proposals for Testing New Subcategories of TNM</b></p> <p>All Tumour Sites 210</p> <p>Head and Neck Tumours 210</p> <p>Digestive System Tumours 211</p> <p>Lung Tumours 213</p> <p>Breast Tumours (ICD‐0‐3 C50) 214</p> <p>Gynaecological Tumours 215</p> <p>Urological Tumours 215</p> <p>References 216</p> <p><b>Chapter 6 Frequently Asked Questions </b></p> <p>General Questions 218</p> <p>Site‐Specific Questions 229</p> <p>References 289</p> <p>Index 291</p> <p>Plate section facing p. 48</p>

<p><b>Christian Wittekind</b>, MD; Professor of Pathology, Chairman Institute of Pathology, University of Leipzig, Germany.</p> <p><b>James D Brierley</b>, BSc, MB, FRCP, FRCR, FRCPC; Professor, Department of Radiation Oncology, Princess Margaret Cancer Centre / University of Toronto, Toronto, Ontario, Canada.</p> <p><b>Anne W. M. Lee</b>, MD; Clinical Professor, Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China.</p> <p><b>Elisabeth van Eycken</b>, MD; Director, Belgium Cancer Registry, Brussels, Belgium.</p>

<p><b>TNM Supplement</b></br> A Commentary on Uniform Use <p>Fifth Edition <p>The Union for International Cancer Control's (UICC) TNM classification system is the most widely used cancer classification and staging system in the world. It is used to describe the anatomical extent of disease and is essential to patient care, research and cancer control. <p>This fifth edition of the <i>TNM Supplement: A Commentary on Uniform Use</i> offers practitioners a wealth of material intended to complement the system's day-to-day use. The volume features: <ul> <li>Updated definitions of terms used in cancer staging.</li> <li>New sections on carcinomas of the thymus, sarcomas of the spine and pelvis, and soft tissue sarcomas of the head and neck, as well as comprehensive updates to sections on head and neck carcinomas, carcinomas of the lung and neuroendocrine tumours.</li> <li>Frequently asked questions from the UICC helpdesk.</li> </ul> <p>The supplement may be treated as a companion text to the recent eighth edition of the<i> TNM Classification of Malignant Tumours</i> (978-1-119-26357-9), supporting the correct and uniform application of the TNM classification system. The<i> TNM Supplement</i> can also be utilised as a standalone book, providing explanations and examples to answer many questions that arise during the daily use of the TNM cancer classification and staging system, particularly in unusual cases.

GB